Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Initiating Eltrombopag (EPAG) Early for aplastic Anemia (AA) may Lead to greater clinical benefits: A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

STShuai TanMSMingyue ShangJNJing Ni

Discussion

Loading...

Member takes

Overview

Meta-analysis shows that early Eltrombopag use improves response rates in aplastic anemia, suggesting better clinical outcomes with concurrent therapy.

Key Points

  • Improved hematological response rates observed with Eltrombopag in aplastic anemia patients.
  • The response rate at 3 months for EPAG+IST was significantly higher at an odds ratio of 2.13.
  • Subgroup analysis indicated optimal outcomes with early Eltrombopag initiation in adults under concurrent therapy.
  • Extending treatment beyond 12 months yielded no significant added benefits, calling for optimized therapy timing.

Cite This Study

Tan et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e06ehttps://doi.org/10.1182/blood-2025-6721
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1This Meta-Analysis Evaluates the Optimal Timing for Initiating and Discontinuing Eltrombopag for Aplastic Anemia2025
  2. 2A Multicenter, Retrospective Study Comparing Immunosuppressive Therapy Combined with Eltrombopag to Immunosuppressive Therapy Alone as Front-Line Treatment for Pediatric Severe Aplastic Anemia2025 · 2 citations
  3. 3Outcomes of eltrombopag combined with immunosuppressive therapy in adults with severe aplastic anemia: A large, propensity-matched retrospective analysis2025
  4. 4Long-term outcomes of intensive immunosuppressive therapy combined with eltrombopag in patients with severe aplastic anemia2025
  5. 5Adding eltrombopag to immunosuppressive treatment with cyclosporine as front-line therapy for moderate aplastic anemia improves trilineage hematologic response: One-year analysis of the randomised, placebo-controlled, double-blind Phase III trial eltrombopag for moderate aplastic anemia (EMAA Trial)2025